Which is Better to Start With DPP-4 Inhibitors or SGLT-2 Inhibitors in Egyptian Diabetic Patients?

Comparative Study of DPP-4 Inhibitors and SGLT-2 Inhibitors in Egyptian Diabetic Patients

Our trial goal is to determine the efficacy and safety of sitagliptin in comparison with empagliflozin in type 2 diabetic Egyptian patients.

Inclusion Criteria:

• Type 2 male/female diabetic patients
• Age 20-70 years
• A1C less than 10.5%

Exclusion Criteria:

• Type 1 diabetes; HbA1c > 10.5%
• Pregnancy
• Chronic liver disease
• Elevated (more than twofold the upper limit of normal) ALT, AST and CPK.
• High bilirubin
• Albumin < 3.5 g/dl
• INR >1-2 Diabetic ketoacidosis
• Urinary tract infection (UTI)
• Pancreatitis < 6 months prior to enrolment
• Renal impairment (creatinine clearance ≤50 ml/min)
• Treatment with anti-obesity drugs or glucagon-like peptide-1 receptor agonists (GLP-1RAs) 3 months prior to enrolment
• Non-compliance with follow-up visits.